Bioventus SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 2, 2026, 4:12 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedBioventus Q3 2026 adjusted EPS of $0.17 beats $0.16 consensus, but revenue of $142.4 million misses $149.5 million estimate and full-year sales guidance of $590 million to $595 million sits below $604.8 million consensus
8-KAug. 5, 2026, 7:40 a.m. ETView on SEC.gov
Results of operations and financial condition · Other events · Financial statements and exhibits